Suppr超能文献

两例急性髓细胞白血病伴侵袭性曲霉菌病患者采用抗真菌联合治疗进行成功的异基因造血干细胞移植。

Successful allogeneic stem cell transplantation in two patients with acute myelogenous leukaemia and invasive aspergillosis by antifungal combination therapy.

出版信息

Mycoses. 2011 Jul;54(4):e255-9. doi: 10.1111/j.1439-0507.2010.01858.x. Epub 2010 Mar 4.

Abstract

Invasive aspergillosis (IA) is an important cause of infectious morbidity and mortality in patients who undergo haematopoietic stem cell transplantation (HSCT). History of IA before allogeneic HSCT is still challenging because of the high risk of recurrence after HSCT. Recent advances in early-stage diagnosis and new, more effective classes of antifungal agents have improved the management of IA in the HSCT recipients. We report two cases with acute myelogenous leukaemia after primary failure of induction chemotherapy with the patients developing pulmonary IA. They responded well to a combination of voriconazole (VCZ) and micafungin, resulting in a remarkable reduction of pulmonary IA lesions at short intervals. Thereafter, antifungal therapy was switched to liposomal amphotericin B (L-AmB), followed by conditioning regimen for allogeneic HSCT, because of the possibility of VCZ altering the metabolism of chemotherapeutic agents and calcineurin inhibitors. Successful engraftment was achieved without severe adverse side-effects or aggravation of IA after HSCT. Combining VCZ with micafungin followed by L-AmB throughout HSCT could be advantageous in stabilising IA in HSCT patients.

摘要

侵袭性曲霉菌病(IA)是造血干细胞移植(HSCT)患者发生传染性发病率和死亡率的重要原因。由于 HSCT 后复发的风险很高,因此异体 HSCT 前的 IA 病史仍然具有挑战性。早期诊断的新进展和新型、更有效的抗真菌药物类别改善了 HSCT 受者中 IA 的治疗管理。我们报告了两例因诱导化疗原发性失败后发生急性髓系白血病并伴有肺部 IA 的患者。他们对伏立康唑(VCZ)和米卡芬净的联合治疗反应良好,在短时间内显著减少了肺部 IA 病变。此后,由于 VCZ 可能改变化疗药物和钙调神经磷酸酶抑制剂的代谢,因此将抗真菌治疗转换为两性霉素 B 脂质体(L-AmB),随后进行同种异体 HSCT 预处理方案。由于没有发生严重的不良反应或在 HSCT 后 IA 恶化,因此成功进行了移植物植入。在 HSCT 期间将 VCZ 与米卡芬净联合使用,随后使用 L-AmB 进行治疗,可能有利于稳定 HSCT 患者的 IA。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验